Suggested remit: To appraise the clinical and cost effectiveness of fruquintinib within its marketing authorisation for treating metastatic colorectal cancer.
|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
|
Reason for decision
|
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
|
| Process |
STA Standard
|
| ID number |
6274
|
Provisional Schedule
| Committee meeting: 2 |
12 December 2024 |
| Expected publication |
05 March 2025 |
Project Team
| Project lead |
Vonda Murray |
Email enquiries
| External Assessment Group |
Health Economics Research Unit and Health Services Research Unit, University of Aberdeen |
Stakeholders
| Companies sponsors |
Takeda (fruquintinib) |
| Others |
Department of Health and Social Care |
| |
Health Technology Wales (HTW) |
| |
NHS England |
| Patient carer groups |
Bowel Cancer UK |
| |
Guts UK |
| Professional groups |
Association of Cancer Physicians |
| |
Cancer Research UK |
| |
Royal College of Physicians |
| |
Royal College of Radiologists |
| Assessment group |
Aberdeen HTA Group |
| Associated public health groups |
None |
| Comparator companies |
Servier Laboratories (trifluridine-tipiracil) (confidentiality agreement signed, participating) |
| |
Bayer (regorafenib) (confidentiality agreement not signed, not participating) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Government |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Institute of Cancer Research |
| |
National Institute for Health Research |
|
Date
|
Update
|
|
08 October 2024 - 29 October 2024
|
Draft guidance |
|
17 July 2024
|
Marketing authorisation has not yet been provided for Fruquintinib for previously treated metastatic colorectal cancer. We are therefore unable to publish the guideline until this is received. |
|
11 July 2024
|
Committee meeting: 1 |
|
05 December 2023
|
Invitation to participate |
|
10 October 2023 - 07 November 2023
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6274 |
|
15 June 2023
|
In progress. DHSC referral received |
|
07 February 2023
|
Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual